1 Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology,2010,139:1481-1496.
2 Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer Tcell defects and human disease. Nat Rev Immunol,2011,11:131-142.
3 Durante-Mangoni E, Wang R, Shaulov A, et al. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol,2004,173:2159-2166.
4 Kumar V. NKT-cell subsets: promoters and protectors in inflammatory liver disease. J Hepatol, 2013, 59:618-620.
5 Arrenberg P, Maricic I, Kumar V. Sulfatide-mediated activation of type Ⅱ natural killer T cells prevents hepatic ischemic reperfusion injury inmice. Gastroenterology, 2011,140:646-655.
6 Schrumpf E, Tan C, Karlsen TH, et al. The biliary epithelium presents antigens to and activates natural killer T cells. Hepatology, 2015,62:1249-1259.
7 Tsuneyama K, Yasoshima M, Harada K, et al. Increased CD1d expression on small bile duct epitheliumand epithelioid granuloma in livers in primary biliary cirrhosis. Hepatology, 1998, 28:620-623.
8 Kita H, Naidenko OV, Kronenberg M, et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology, 2002,123:1031-1043.
9 Mencarelli A, Renga B, Migliorati M, et al. The bile acid sensor farnesoid X receptor is a modulator ofliver immunity in a rodent model of acute hepatitis. J Immunol, 2009, 183:6657-6666.
10 Mattner J, Savage PB, Leung P, et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe, 2008, 3:304-315. |
